argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-15 08:34 |
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye D…
|
English | 133.7 KB | ||
| 2025-11-19 07:55 |
argenx Announces Results of Extraordinary General Meeting of Shareholders
|
English | 23.3 KB | ||
| 2025-10-30 08:21 |
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
|
English | 175.7 KB | ||
| 2025-10-30 06:26 |
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad …
|
English | 216.7 KB | ||
| 2025-10-23 08:17 |
argenx to Report Third Quarter 2025 Financial Results and Business Update on Oc…
|
English | 22.3 KB | ||
| 2025-10-15 08:11 |
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM…
|
English | 280.9 KB | ||
| 2025-10-06 07:54 |
argenx announces Extraordinary General Meeting of Shareholders on November 18, …
|
English | 24.3 KB | ||
| 2025-08-28 09:40 |
argenx to Present at Upcoming Investor Conferences
|
English | 98.5 KB | ||
| 2025-08-25 08:33 |
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in …
|
English | 180.4 KB | ||
| 2025-08-19 07:54 |
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
|
English | 21.5 KB | ||
| 2025-08-12 13:54 |
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia …
|
English | 94.6 KB | ||
| 2025-07-31 08:20 |
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Bus…
|
English | 164.9 KB | ||
| 2025-07-31 07:31 |
argenx SE, Halfjaarlijkse financiële verslaggeving
|
English | 1.0 MB | ||
| 2025-07-24 08:15 |
argenx to Report Half Year 2025 Financial Results and Second Quarter Business U…
|
English | 169.3 KB | ||
| 2025-06-30 07:51 |
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndr…
|
English | 50.6 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
